Preventable Toxicity: The Pharmacogenomics Case for DPYD Testing in Oncology | Precision Medicine Pharmacist Podcast
Fluoropyrimidines such as 5-fluorouracil (5-FU) and capecitabine remain cornerstone chemotherapies in oncology. However, for patients with certain DPYD gene variants, these commonly used drugs can cause life-threatening toxicities due to impaired metabolism of the active compounds. In this episode of the Precision Medicine Pharmacist Podcast, host Melissa Smith, PharmD, explores how DPYD genotyping is transforming oncology care by helping clinicians identify patients at risk before toxicity occurs. Joined by Karen Merritt, an advocate for universal DPD testing and leader with the Test4DPD initiative, the discussion sheds light on how pharmacogenomics is shaping safer, more personalized cancer treatment. Together, they explore current evidence, new FDA updates, and implementation frameworks that empower pharmacists and oncology teams to prevent preventable harm through precision medicine. 🧠 Key Discussion Topics
- The science behind DPYD gene variants and their clinical implications
- How undiagnosed DPD deficiency contributes to preventable toxicity
- New recommendations from the CPIC® Guideline for Fluoropyrimidines and DPYD
- Insights from the Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines
- Advocacy for universal DPYD testing across oncology centers
- How pharmacists can champion pharmacogenomic testing integration in oncology workflows
- Updates from the FDA-approved labeling for Xeloda (capecitabine)
You May Also Like

Chascas Largas: Freedom Archives
Chascas Largas

Noticias de la mañana
Noticias Telemundo

24/7 News: The Latest
iHeartPodcasts and TTWN

teleSUR Podcast
teleSUR

15 Minutos - Gazeta do Povo
GAZETA DO POVO

Sputnik Arabic
Sputnik Arabic

The True Crime Tapes
Bobby Capucci

All Steelers Talk
All Steelers Talk

News - اخبار
Iran International - ایران اینترنشنال

Asmongold TV
Asmongold TV
Community discussion